Safety and efficacy of an escalating dose regimen of pegylated interferon alpha-2b in the treatment of haemodialysis patients with chronic hepatitis C

Journal of Viral Hepatitis

Volumn 17, Issue 6, 2010, Pages 410-418

  Tan, S S ^a   Abu Hassan, M R ^b   Abdullah, A ^a   Ooi, B P ^b   Korompis, T ^c   Merican, M I ^a  

^a Hospital Selayang   (Malaysia)

^b Alor Setar Hospital Malaysia   (Malaysia)

^c Schering Plough   (Singapore)

Author keywords

Chronic hepatitis C; Escalating dose regimen; Haemodialysis; Kidney; Pegylated interferon alpha 2b; Renal dysfunction

Indexed keywords

PEGINTERFERON ALPHA2B; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HUMAN; INFECTION; LETHARGY; LUNG EDEMA; MALE; MORBIDITY; MORTALITY; NAUSEA; PARAPLEGIA; PRIORITY JOURNAL; SEIZURE; SINGLE BLIND PROCEDURE; THYROID FUNCTION TEST; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; VISUAL IMPAIRMENT; ADOLESCENT; CHEMICALLY INDUCED; CLASSIFICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANEMIA; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RENAL DIALYSIS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 77952256322     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01191.x     Document Type: Article

References (27)

1. Fissell RB, Bragg-Gresham JL, Woods JD et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004 65 (6 2335 2342.
2. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002 36 (1 3 10.
3. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000 11 (10 1896 1902.
4. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004 20 (11-12 1271 1277.
5. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 (9286 958 965.
6. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 (13 975 982.
7. Mangia A, Santoro R, Minerva N et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005 352 (25 2609 2617.
8. von Wagner M, Huber M, Berg T et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005 129 (2 522 527.
9. Schering Corporation. Rebetol® (ribavirin, USP) Capsules and Oral Solution.
10. Hoffman-LaRoche, Inc. Pegasys (peginterferon alfa-2a).
11. Schering Corporation. PegIntron (peginterferon alfa-2b) Injection.
12. Fabrizi F, Dixit V, Messa P, Martin P. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2008 15 (2 79 88.
13. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis 2008 51 (2 263 277.
14. Fabrizi F, Lunghi G, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther 2006 24 (10 1413 1422.
15. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006 13 (5 316 321.
16. Covic A, Maftei I-D, Mardare NGI et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol 2006 19 (6 794 801.
17. Kokoglu OF, Ucmak H, Hosoglu S et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 2006 21 (3 575 580.
18. Liu CH, Liang CC, Lin JW et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 2008 57 (4 525 530.
19. Rendina M, Schena A, Castellaneta NM et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007 46 (5 768 774.
20. Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon α-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006 21 (2 437 443.
21. Sporea I, Popescu A, Sirli R et al. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol 2006 12 (26 4191 4194.
22. Annicchiarico BE, Siciliano M. Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C. Aliment Pharmacol Ther 2004 20 (1 123 124.
23. Amarapurkar DN, Patel ND, Kirpalani AL. Monotherapy with peginterferon alpha-2b (12 kDa) for chronic hepatitis C infection in patients undergoing haemodialysis. Trop Gastroenterol 2007 28 (1 16 18.
24. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Kidney Int 2008 73 (Suppl 109) : S1 S99.
25. Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004 40 (6 993 999.
26. Yu ML, Dai CY, Huang JF et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008 47 (6 1884 1893.
27. Yu M-L, Dai C-Y, Huang J-F et al. A randomised study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007 56 (4 553 559.